Loading clinical trials...
Loading clinical trials...
Phase 2 Study With the Multi-Targeted Tyrosine-Kinase Inhibitor Pazopanib (GW786034) for Patients With Relapsed or Refractory Urothelial Cancer
Conditions
Interventions
pazopanib hydrochloride
fludeoxyglucose F 18
Locations
1
Italy
Fondazione Istituto Nazionale dei Tumori
Milan, Italy
Start Date
December 1, 2009
Primary Completion Date
December 1, 2011
Completion Date
August 1, 2012
Last Updated
August 12, 2013
NCT00026884
NCT07061964
NCT04235764
NCT03375307
NCT07050771
NCT04585750
Lead Sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions